Skip to main content

Table 1 Subject clinical details

From: Stable HIV-1 integrase diversity during initial HIV-1 RNA Decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy

Subject DS1 DS2 DS3 DS4
Gender Male Male Male Female
Age 61 39 49 44
Date of diagnostic 13/05/96 01/01/90 01/07/87 01/01/91
Transmission type Heterosexual IVDU IVDU IVDU
Previous ART lines 9 6 12 12
#drugs before RAL 13 9 13 12
New drugs started alongside RAL DRV DRV DRV,ETV, T-20 DRV,MVC
Previous exposure     
NRTI YES YES YES YES
NNRTI YES YES YES YES
PI YES YES YES YES
T-20 NO NO NO NO
ART ddI + 3TC + DRV/r + RAL TDF/FTC + DRV/r + RAL TDF/FTC + DRV/r + RAL + T-20 DRV/r + RAL + MVC
GSS 4 3.5 3.5 3.5
Baseline CD4 (cells/mm 3) 614 300 332 399
  1. Intravenous Drug Use (IVDU); Genotypic Sensitivity Score (GSS, Stanford HIVdb), NRTI: Nucleoside-analogues Reverse Transcriptase Inhibitor; NNRTI non- Nucleoside-analogues Reverse Transcriptase Inhibitor; PI: Protease Inhibitor; Darunavir (DRV); Didanosine (DDI); Lamivudine (3TC); Raltregravir (RAL); Ritonavir (RTV); Emtricitabine (FTC); Tenofovir (TDF); Etravirine (ETV); Enfuvirtide (T-20); Maraviroc (MVC).